As a result, the KEYNOTE-001 trial enrolled untreated patients affected by NSCLC, treated them with pembrolizumab at a dose of 10 mg per kilogram every 2 or 3 weeks, and demonstrated that 12-month Overall Survival (OS) was higher among patients with a PD-L1 TPS ≥ 50% (85%) when compared with the overall population (71%) [6]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.